JFrog stock rises as Cantor Fitzgerald maintains Overweight rating after strong Q2
Wendell Amy McBride, a director at Axogen Inc . (NASDAQ:AXGN), a company that has seen its stock surge over 100% in the past year with a current market capitalization of $810 million, sold 5,000 shares of the company’s common stock on March 3, according to a recent SEC filing. The shares were sold at a weighted average price of $20.02 each, resulting in a total transaction value of $100,100. Following the sale, McBride retains ownership of 97,899 shares of Axogen stock. These transactions were conducted under an approved Rule 10b5-1 trading plan, which allows company insiders to set up a predetermined schedule for buying or selling stock. According to InvestingPro analysis, Axogen appears slightly overvalued at current levels, despite showing strong momentum with a 37% gain over the past six months. For comprehensive insider trading analysis and 12 additional ProTips about Axogen, subscribers can access the full Pro Research Report.
In other recent news, AxoGen, Inc. reported strong financial results, with fourth-quarter sales reaching $49.4 million, a 15.1% increase year over year, surpassing JMP Securities’ prior estimate of $46.1 million. The company forecasts a revenue growth rate of 15-17% for 2025, translating to $215.4 million to $219.1 million, exceeding JMP’s midpoint expectation. Canaccord Genuity raised its price target for AxoGen to $26 from $22, maintaining a Buy rating, reflecting confidence in the company’s strategic direction and performance. Similarly, Raymond (NSE:RYMD) James increased its price target to $25, keeping an Outperform rating, highlighting AxoGen’s projected 15-20% compound annual growth rate in revenue. Cantor Fitzgerald reaffirmed an Overweight rating with a $24 price target, noting AxoGen’s market expansion plans and product portfolio growth. The company’s Avance Nerve Graft is poised for a significant milestone with anticipated Biologics License Application approval, which could provide 12+ years of market exclusivity. Analysts at Citizens JMP also maintained a Market Outperform rating with a $26 target, emphasizing the potential impact of this regulatory milestone. AxoGen continues to focus on expanding its market presence and enhancing product adoption under the leadership of its new CEO, Mike Dale.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.